domingo, 9 de junio de 2019

Twenty years of Lithium pharmacogenetics: A systematic review. - PubMed - NCBI

2019 May 23;278:42-50. doi: 10.1016/j.psychres.2019.05.036. [Epub ahead of print]

Twenty years of Lithium pharmacogenetics: A systematic review.

Pagani R1, Gasparini A2, Ielmini M2, Caselli I2, Poloni N2, Ferrari M3, Marino F3, Callegari C4.

Author information

Abstract

Lithium is among the best proven treatments for patients diagnosed with Bipolar Disorder, however response to Lithium appears to be considerably variable among individuals and it has been suggested that this inconstancy in Lithium response could be genetically determined. Starting from this perspective, in the last few decades, a number of pharmacogenetic studies have attempted to identify genetic variants, which might be associated with response to Lithium in bipolar patients, in order to develop a pharmacogenetics test to tailor treatment on patients, identifying who will benefit the most from therapy with Lithium. Within this context, authors have critically reviewed pharmacogenetic studies of Lithium response in bipolar disorder, suggesting strategies for future work in this field. Computerized searches of PubMed and Embase databases, for studies published between 1998 and January 2018, was performed: 1162 studies were identified but only 37 relevant papers were selected for detailed review. Despite some interesting preliminary findings, the pharmacogenetics of Lithium and the development of a specific pharmacogenetics test in bipolar disorder appears to be a field still in its infancy, even though the advent of genome-wide association studies holds particular promise for future studies, which should include larger samples.